Hengrui Medicine Buys Back 13.75 Million Shares, Spending 853 Million Yuan
Hengrui Medicine announced on July 19th that it has repurchased 13.75 million A-share common stocks, representing 0.21% of the company's total share capital. The buyback initiative, approved by the company's ninth board of directors on August 20, 2025, is intended for an employee stock ownership plan. The repurchase occurred within a price range of 45.3 to 70 yuan per share, with the total funds utilized amounting to 853 million yuan, excluding transaction fees. The company initially planned to spend between 1 billion and 2 billion yuan on the buyback, with the maximum repurchase price set at 90.85 yuan per share. The buyback period was designated as 12 months from the date of board approval. As of July 19, 2026, the company had cumulatively repurchased 13,750,200 shares.
Hengrui Medicine's share buyback program, aimed at funding an employee stock ownership plan, demonstrates a strategic approach to aligning employee interests with corporate performance. By utilizing treasury shares, the company signals confidence in its future valuation and seeks to incentivize its workforce. The executed buyback, falling within the lower end of the planned spending range and below the maximum price, suggests a potentially favorable market entry point for the company. This action could be viewed as a mechanism to manage share price fluctuations and retain talent in a competitive pharmaceutical landscape. Future performance will indicate the long-term efficacy of this incentive structure in driving sustained growth and value creation.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.